Neurocrine Biosciences, Inc. (NBIX)
After hours:
| Previous close | 138.97 |
| Open | 139.37 |
| Bid | 137.68 x 100 |
| Ask | 137.81 x 100 |
| Day's range | 136.06 - 139.37 |
| 52-week range | 89.04 - 148.37 |
| Volume | |
| Avg. volume | 885,879 |
| Market cap | 13.856B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 55.77 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | N/A |
- PR Newswire
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the community in managing the condition.
- PR Newswire
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be
- GlobeNewswire
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicine
